Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01137838

IM101-238

Details and patient eligibility

About

To compare the proportion of rheumatoid arthritis (RA) patients prescribed opioids, benzodiazepines, and antidepressants before versus after starting each of the following biologics: abatacept, infliximab, etanercept, adalimumab, utilizing an administrative claims database.

Enrollment: 1,810 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• ICD 9 diagnosis RA 714.0
• Documented first biologic prescription ("index" prescription) for abatacept, infliximab, etanercept, or adalimumab
• Continuous therapy (gap between scripts no greater than 150% days supply) for minimum 6 months from index
• Prescription claims data available for 6 months before and 12 months after index biologic prescription
• Continuous eligibility for 6 months before and 12 months after index biologic prescription

Exclusion criteria

• Prescription claims for another biologic during the observation period (including rituximab and anakinra)
• Prescriptions not continuous for at least 6 months

Trial design

1,810 participants in 4 patient groups

Patients with RA and new to abatacept

Patients with RA and new to infliximab

Patients with RA and new to etanercept

Patients with RA and new to adalimumab